Bausch + Lomb, a prominent global eye health company listed on the Toronto Stock Exchange under BLCO, has recently partnered with Alfa Instruments to distribute and commercialize Alfa Instruments’ line of surgical intraocular dyes worldwide, excluding Italy.
This exclusive distribution agreement strengthens Bausch + Lomb’s surgical portfolio by introducing Alfa Instruments’ innovative intraocular dyes, which have demonstrated success in the European Union. Alfa Instruments, based in Italy, brings over 60 years of experience in the pharmaceutical industry, specializing in manufacturing, developing, and marketing ophthalmic products for surgical and diagnostic purposes.
Joe Gordon, President of Global Consumer and Vision Care at Bausch + Lomb, emphasized the significance of adding Alfa Instruments’ proven product to their comprehensive surgical portfolio, which currently features over 400 products. These intraocular dyes are designed to improve visibility of targeted eye tissues and aid in identifying transparent eye layers during vitreoretinal, corneal, and cataract surgeries.
Bausch + Lomb’s commitment to providing innovative products to eye care professionals is reflected in their partnership with Alfa Instruments. The company intends to distribute and commercialize the surgical intraocular dyes globally, excluding Italy, where Alfa Instruments established a new manufacturing site in recent years.
Under the terms of the agreement, Bausch + Lomb will oversee all distribution and commercial activities related to Alfa Instruments’ Vitreocare intraocular dyes, including Vitreo Lutein, Single Lutein Blue, Double Lutein Blue, Phaco Lutein, and Trypan Blue. These dyes contain lutein, a natural blue light filter, and Pure Benzyl-Brilliant Blue (PBB), which enhances their binding affinity and reduces diffusion into retinal layers.
Alfa Instruments’ surgical dyes, which are CE-marked and currently available in the EU, UK, and Switzerland, will soon be distributed in all EU countries except Italy in the first half of 2023. Both companies are actively working on regulatory approvals for the surgical dyes in other markets.
Fabio David, CEO of Alfa Instruments, expressed enthusiasm for the collaboration with Bausch + Lomb, a renowned leader in global eye care. He highlighted the opportunity to expand access to their intraocular dyes through Bausch + Lomb’s extensive distribution network and looks forward to enhancing vision outcomes for patients undergoing various eye surgeries.
